AU6030494A - Method for treating myofascial pain syndrome - Google Patents

Method for treating myofascial pain syndrome

Info

Publication number
AU6030494A
AU6030494A AU60304/94A AU6030494A AU6030494A AU 6030494 A AU6030494 A AU 6030494A AU 60304/94 A AU60304/94 A AU 60304/94A AU 6030494 A AU6030494 A AU 6030494A AU 6030494 A AU6030494 A AU 6030494A
Authority
AU
Australia
Prior art keywords
pain
muscle
agent
patient
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU60304/94A
Other languages
English (en)
Inventor
Gary E Borodic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Associated Synapse Biologics
Original Assignee
Associated Synapse Biologics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Associated Synapse Biologics filed Critical Associated Synapse Biologics
Publication of AU6030494A publication Critical patent/AU6030494A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU60304/94A 1993-01-15 1994-01-13 Method for treating myofascial pain syndrome Abandoned AU6030494A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US005040 1979-01-22
US504093A 1993-01-15 1993-01-15
PCT/US1994/000626 WO1994015629A1 (en) 1993-01-15 1994-01-13 Method for treating myofascial pain syndrome

Publications (1)

Publication Number Publication Date
AU6030494A true AU6030494A (en) 1994-08-15

Family

ID=21713832

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60304/94A Abandoned AU6030494A (en) 1993-01-15 1994-01-13 Method for treating myofascial pain syndrome

Country Status (5)

Country Link
EP (1) EP0679090A1 (ja)
JP (1) JP4381477B2 (ja)
AU (1) AU6030494A (ja)
CA (1) CA2153781A1 (ja)
WO (1) WO1994015629A1 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
AU688452B2 (en) * 1993-12-28 1998-03-12 Allergan, Inc. Botulinum toxins for treating various disorders and associated pain
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
WO1995030431A1 (en) * 1994-05-09 1995-11-16 Binder William J Method for reduction of headache pain
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7691983B2 (en) 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053005A (en) * 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals

Also Published As

Publication number Publication date
WO1994015629A1 (en) 1994-07-21
CA2153781A1 (en) 1994-07-21
JPH08508241A (ja) 1996-09-03
EP0679090A1 (en) 1995-11-02
JP4381477B2 (ja) 2009-12-09

Similar Documents

Publication Publication Date Title
AU6030494A (en) Method for treating myofascial pain syndrome
Ropper et al. Pain in Guillain-Barré syndrome
US6632433B2 (en) Method for treating cervical dystonia with botulinum toxin type B
EP1757325B1 (en) Use of botulinum toxin for treating myofascial pain
Meythaler et al. Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report
US8187612B2 (en) Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
EP1487481A2 (en) Methods of treating nerve entrapment syndromes
Ward et al. The management of pain in spasticity
WO2003063898A2 (en) Method of treating pain with botulinum toxin
US8557256B2 (en) Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
Wilk Surgical management of refractory craniomandibular pain using radiofrequency thermolysis: a report of thirty patients
Fotiadis et al. Hemiplegic shoulder syndrome: Possible underlying neurophysiological mechanisms
Glenn et al. Chemical denervation for the treatment of hypertonia and related motor disorders: phenol and botulinum toxin
DO WEBB et al. Current Concepts in Treating Hemiplegic Shoulder Pain
Morton et al. The role of botulinum toxin in the management of cerebral palsy
AU727737B2 (en) Method for treating dysphagia
Kanji Convergent referred muscle pain: a case series using a segmental approach for chronic pain without pathology
AU2005200248B2 (en) Method for treating dystonia with botulinum toxin type B
CA2300666C (en) Method for treating dystonia with botulinum toxin type b
CA2589987C (en) Method for treating a cholinergic influenced secretion
Guerri A SYSTEMATIC REVIEW OF OBSERVATIONAL STUDIES OF PATIENTS WITH OCULAR HYPERTENSION OR GLAUCOMA RECEIVING LONG TERM TOPICAL EYE THERAPIES
Tait et al. Musculoskeletal Pain Syndromes
Center et al. Home/Blog/Where does back pain come from?
AU1636700A (en) Method for treating dystonia with botulinum toxin type B
AU2003202374A1 (en) Method of treating pain with botulinum toxin